肾康注射液治疗慢性肾炎患者的近期疗效及对炎症因子水平的影响

[目的]探讨肾康注射液治疗慢性肾炎患者的近期疗效及对炎症因子水平的影响.[方法]84例慢性肾炎患者随机分为两组,各42例,对照组给予缬沙坦治疗,观察组在对照组治疗的基础上加用肾康注射液治疗.比较两组患者的近期临床疗效及中医症状积分、炎性因子、肾功能的变化.[结果]治疗3个月后,观察组总有效率为83.33%(35/42),明显高于对照组61.90%(26/42)(P<0.05);观察组24 h尿蛋白、β2微球蛋白及血清肿瘤坏死因子-α、白介素-6和白介素-8均明显低于对照组(P<0.05);观察组中医症状积分明显低于对照组,且两组相比较差异有显著性(P<0.05).[结论]肾康注射液可提高慢性肾炎患者的临床疗效,改善患者近期肾功能和临床症状,减轻炎症反应,且未增加不良反应的发生,值得临床重视.

Effect of Shenkang Injection on the Clinical Efficacy and the level of Inflammatory Factors in Patients with Chronic Glomerulonephritis

[Objective]To investigate the effect of Shenkang injection on the clinical efficacy and the level of inflammatory factors in patients with chronic glomerulonephritis treatment.[Methods]Eighty-four cases of patients with chronic nephritis were random divided into two groups, 42 cases in each.The control group was treated with valsartan.On the basis of the control group, the observation group was treated with Shenkang injection.After three months of treatment, the clinical curative effect and TCM symptom integral, inflammatory factors and renal function were compared between the two groups.[Results] After 3 months of treatment, the total effective rate of the observation group was 83.33%(35/42), which was significantly higher than that of the control group 61.90%(26/42) (P<0.05);The 24hUPr,β2-MG ,TNF-α, IL-6 and IL-8 in the observation group were significantly lower than those in the control group (P<0.05);The TCM symptom score of the observation group was significantly lower than that of the control group and there was significant difference between the two groups (P<0.05).[Conclusion] Shenkang injection can improve the clinical curative effect of chronic nephritis patients, improve renal function and clinical symptoms, reduce inflammation with less adverse reactions, it is worthy of attention.